Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2013 | 1 |
2015 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean
yusuf ko
(7 results)?
Highly specific σ2R/TMEM97 ligand alleviates neuropathic pain and inhibits the integrated stress response.
bioRxiv [Preprint]. 2023 Oct 17:2023.04.11.536439. doi: 10.1101/2023.04.11.536439.
bioRxiv. 2023.
PMID: 37090527
Free PMC article.
Updated.
Preprint.
We sought to understand this unique anti-neuropathic pain effect by addressing two key questions: do these sigma(2)R/TMEM97 compounds act selectively via the receptor, and what is their downstream mechanism on nociceptive neurons? Using male and female conventional knockout (K …
We sought to understand this unique anti-neuropathic pain effect by addressing two key questions: do these sigma(2)R/TMEM97 compounds act se …
PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells.
Rah B, ur Rasool R, Nayak D, Yousuf SK, Mukherjee D, Kumar LD, Goswami A.
Rah B, et al.
Autophagy. 2015;11(2):314-31. doi: 10.1080/15548627.2015.1017182.
Autophagy. 2015.
PMID: 25803782
Free PMC article.
This inhibition of BECN1 in CaP cells, leading to the disruption of the BCL2-BECN1 interaction by overexpressed PAWR has not been reported so far. Third, we provide evidence that pawr-KO MEFs exhibited abundant autophagy signs even at toxic concentrations of 3-AWA undersco …
This inhibition of BECN1 in CaP cells, leading to the disruption of the BCL2-BECN1 interaction by overexpressed PAWR has not been reported s …
Item in Clipboard
A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study.
Zhang W, Kim D, Philip E, Miyan Z, Barykina I, Schmidt B, Stein H; Gluco VIP study.
Zhang W, et al.
Clin Drug Investig. 2013 Apr;33(4):263-74. doi: 10.1007/s40261-013-0063-3.
Clin Drug Investig. 2013.
PMID: 23435929
Item in Clipboard
Cite
Cite